Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

被引：6

作者：

Bazhenova, L. ^{[1
]}

Liu, S. V. ^{[2
]}

Lin, J. J. ^{[3
]}

Lu, S. ^{[4
]}

Drilon, A. ^{[5
]}

Chawla, S. P. ^{[6
,7
]}

Fakih, M. ^{[8
]}

Krzakowski, M. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Blakely, C. ^{[11
]}

Buchschacher, G. L., Jr. ^{[12
]}

Cassier, P. ^{[13
]}

Fan, Y. ^{[14
]}

Folprecht, G. ^{[15
]}

McCallum, S. ^{[16
]}

Pitcher, B. ^{[17
]}

Chen, D. ^{[18
]}

Freund, R. ^{[19
]}

Springfeld, C. ^{[20
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, Dept Med, San Diego, CA 92103 USA

[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[3] Massachusetts Gen Hosp, Dept Hematol Oncol, Canc Ctr, Boston, MA 02114 USA

[4] Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Sarcoma Oncol Ctr, Santa Monica, CA USA

[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[9] Maria Sklodowska Curie Inst, Dept Lung & Chest Canc, Ctr Oncol, Warsaw, Poland

[10] Univ Complutense Ciberonc, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO H12o Lung Canc Clin Res Unit, Madrid, Spain

[11] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[12] Los Angeles Med Ctr, Dept Hematol Oncol, Kaiser Permanente Southern Calif, Los Angeles, CA USA

[13] Ctr Leon Berard, Dept Med, Lyon, France

[14] Zhejiang Canc Hosp, Med Dept Thorac Oncol, Hangzhou, Peoples R China

[15] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept Unit Med Oncol, Dresden, Germany

[16] Genentech Inc, Medicat Safety & Risk Management, San Francisco, CA 94080 USA

[17] F Hoffmann La Roche Ltd, Stat Sci, Mississauga, ON, Canada

[18] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Med Oncol, Basel, Switzerland

[20] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

533P

引用

页码：S598 / S599

页数：2

共 50 条

[41] Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib
Dziadziuszko, Rafal
Hung, Tiffany
Wang, Kun
Choeurng, Voleak
Drilon, Alexander
Doebele, Robert C.
Barlesi, Fabrice
Wu, Charlie
Dennis, Lucas
Skoletsky, Joel
Woodhouse, Ryan
Li, Meijuan
Chang, Ching-Wei
Simmons, Brian
Riehl, Todd
Wilson, Timothy R.
MOLECULAR ONCOLOGY, 2022, 16 (10) : 2000 - 2014
[42] Efficacy and Safety of Larotrectinib in Pediatric Patients with NTRK Fusion-Positive Primary Central Nervous System (CNS) Tumors
Goto, Hiroaki
PEDIATRIC BLOOD & CANCER, 2021, 68
[43] Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
LANCET ONCOLOGY, 2020, 21 (08): : E372 - E372
[44] Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Doebele, R.
Ahn, M.
Siena, S.
Drilon, A.
Krebs, M.
Lin, C.
De Braud, F.
John, T.
Tan, D.
Seto, T.
Dziadziuszko, R.
Arkenau, H.
Barlesi, F.
Rolfo, C.
Wolf, J.
Chow-Maneval, E.
Multani, P.
Cui, N.
Riehl, T.
Cho, B. C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S322
[45] Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Rolfo, C.
Dziadziuszko, R.
Doebele, R. C.
Demetri, G.
Simmons, B.
Huang, X.
Ye, C.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2019, 30
[46] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)
Liu, S. V.
De Braud, F.
Drilon, A.
Doebele, R. C.
Patel, M. R.
Cho, B. C.
Ahn, M. J.
Chiu, C. H.
Farago, A. F.
Goto, K.
Lee, J.
Ohe, Y.
Ou, S. H. I.
Cassier, P.
Tan, D. S. W.
Otterson, G. A.
Veronese, L.
Osborne, S.
Simmons, B.
Siena, S.
ANNALS OF ONCOLOGY, 2021, 32 (04) : 577 - 577
[47] Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
Dawood, Shaheenah
Ali, Zulfaqqar Jaffar
CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 1451 - 1459
[48] Entrectinib Approved for NTRK Fusion-Positive Solid Tumors and ROS1-Rearranged Non-Small Cell Lung Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
[49] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Liu, Dazhi
Offin, Michael
Harnicar, Stephen
Li, Bob T.
Drilon, Alexander
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
[50] Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Solomon, B. J.
Drilon, A.
Lin, J. J.
Bazhenova, L.
Goto, K.
De langen, J.
Kim, D-W.
Wolf, J.
Springfeld, C.
Popat, S.
Lim, D. W-T.
Baik, C. S.
Hervieu, A.
Garcia, V. Moreno
Yang, N.
Thamake, S.
Ades, F.
Trone, D.
Besse, B.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →